Abstract
During the last years the development of approaches to multitarget drug design and discovery is gaining acceptance. The cannabinoids are potentially excellent multi-target drug candidates because of their interesting pharmacological profiles, among which stands out the dual capacity of cannabinoid ligands to act as cannabinoid agonist and cholinesterase inhibitors. In this article, inhibition, kinetics studies and docking simulations with a representative set of cannabinoids are presented. The results of these studies showed the inhibitory capacity of some agonist cannabinoids with selectivity at AChE or BuChE enzymes. The kinetic and modelling studies allowed us to postulate the potential mode of action and the binding site of the cannabinoids. In general, the studied cannabinoids showed a mixed type inhibition mode of action. The exception to this behaviour was found for the agonist CP-55,940 that showed a non-competitive inhibition, suggesting that this cannabinoid only binds to the peripheral site.
Keywords: Alzheimer disease, agonist cannabinoids, cholinesterase inhibitors, multitarget drugs
Current Alzheimer Research
Title:Multitarget Cannabinoids as Novel Strategy for Alzheimer Disease
Volume: 10 Issue: 3
Author(s): Pedro Gonzalez-Naranjo, Nuria E. Campillo, Concepcion Perez and Juan A. Paez
Affiliation:
Keywords: Alzheimer disease, agonist cannabinoids, cholinesterase inhibitors, multitarget drugs
Abstract: During the last years the development of approaches to multitarget drug design and discovery is gaining acceptance. The cannabinoids are potentially excellent multi-target drug candidates because of their interesting pharmacological profiles, among which stands out the dual capacity of cannabinoid ligands to act as cannabinoid agonist and cholinesterase inhibitors. In this article, inhibition, kinetics studies and docking simulations with a representative set of cannabinoids are presented. The results of these studies showed the inhibitory capacity of some agonist cannabinoids with selectivity at AChE or BuChE enzymes. The kinetic and modelling studies allowed us to postulate the potential mode of action and the binding site of the cannabinoids. In general, the studied cannabinoids showed a mixed type inhibition mode of action. The exception to this behaviour was found for the agonist CP-55,940 that showed a non-competitive inhibition, suggesting that this cannabinoid only binds to the peripheral site.
Export Options
About this article
Cite this article as:
Gonzalez-Naranjo Pedro, E. Campillo Nuria, Perez Concepcion and A. Paez Juan, Multitarget Cannabinoids as Novel Strategy for Alzheimer Disease, Current Alzheimer Research 2013; 10 (3) . https://dx.doi.org/10.2174/1567205011310030002
DOI https://dx.doi.org/10.2174/1567205011310030002 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Multivariate Optimization Model in a Partial Least Squares-1 Method for Simultaneous Determination of Dorzolamide Hydrochloride and Timolol Maleate in Eye Drops
Current Pharmaceutical Analysis The Effects of CCRC on Cognition and Brain Activity in aMCI Patients: A Pilot Placebo Controlled BOLD fMRI Study
Current Alzheimer Research Galanin/GALP Receptors and CNS Homeostatic Processes
CNS & Neurological Disorders - Drug Targets Brain Aging and Disorders of the Central Nervous System: Kynurenines and Drug Metabolism
Current Drug Metabolism Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Evaluation of Mental Status HIV-Infected Patients: Implications for Treatment
Current HIV Research Potential of Photobiomodulation to Induce Differentiation of Adipose- Derived Mesenchymal Stem Cells into Neural Cells
Current Stem Cell Research & Therapy Bioinformatic Analysis Reveals Key Genes and Pathways in Aging Brain of Senescence-accelerated Mouse P8 (SAMP8)
CNS & Neurological Disorders - Drug Targets Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Harmaline and its Derivatives Against the Infectious Multi-Drug Resistant Escherichia coli
Medicinal Chemistry Common Pathways in Health Benefit Properties of RSV in Cardiovascular Diseases, Cancers and Degenerative Pathologies
Current Pharmaceutical Biotechnology Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Integrated Genomic Analysis Revealed Associated Genes for Alzheimer’s Disease in APOE4 Non-Carriers
Current Alzheimer Research Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Thiamine and Alcohol for Brain Pathology: Super-imposing or Different Causative Factors for Brain Damage?
Current Drug Abuse Reviews Repurposed Drugs in Metabolic Disorders
Current Topics in Medicinal Chemistry Flavonoids from Stem and Leaf of <i>Scutellaria Baicalensis</i> Georgi Inhibit the Phosphorylation on Multi-sites of Tau Protein Induced by Okadaic Acid and the Regulative Mechanism of Protein Kinases in Rats
Combinatorial Chemistry & High Throughput Screening Cyclooxygenases Regulation by Estradiol on Endothelium
Current Pharmaceutical Design Can an Apple a Day Keep the Doctor Away?
Current Pharmaceutical Design Intermittent Transient Motor Aphasia Associated with Acute Lithium Toxicity: A Case Report and Brief Review
Current Drug Safety